In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
News|Articles|June 23, 2026
Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action
Author(s)Louie Pasculli
Fact checked by: Marco Meglio
The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.
Advertisement
Advertisement
June is Alzheimer’s & Brain Awareness Month, an annual observance dedicated to raising awareness of Alzheimer disease (AD), related dementias, and the importance of maintaining brain health across the lifespan. Established by the Alzheimer’s Association in 2014, the campaign highlights the growing burden of AD while promoting education on risk reduction, early detection, diagnosis, and advances in research and treatment.
Related to this article
In recognition of World Alzheimer's Day, NeurologyLive reviews Alzheimer disease developments from 2026, spanning blood-based biomarkers, emerging treatments, prevention research, disease risk factors, and safety considerations surrounding anti-amyloid therapies.
The phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.
PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement